Galecto (GLTO) Competitors $3.35 -0.02 (-0.59%) As of 03:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GLTO vs. ASBP, MTEX, HOTH, MRKR, PMN, BFRG, LPCN, CASI, LPTX, and FLGCShould you be buying Galecto stock or one of its competitors? The main competitors of Galecto include Aspire Biopharma (ASBP), Mannatech (MTEX), Hoth Therapeutics (HOTH), Marker Therapeutics (MRKR), ProMIS Neurosciences (PMN), Bullfrog AI (BFRG), Lipocine (LPCN), CASI Pharmaceuticals (CASI), Leap Therapeutics (LPTX), and Flora Growth (FLGC). These companies are all part of the "pharmaceutical products" industry. Galecto vs. Its Competitors Aspire Biopharma Mannatech Hoth Therapeutics Marker Therapeutics ProMIS Neurosciences Bullfrog AI Lipocine CASI Pharmaceuticals Leap Therapeutics Flora Growth Aspire Biopharma (NASDAQ:ASBP) and Galecto (NASDAQ:GLTO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, community ranking, dividends, analyst recommendations, institutional ownership, earnings and risk. Does the MarketBeat Community prefer ASBP or GLTO? Galecto received 32 more outperform votes than Aspire Biopharma when rated by MarketBeat users. Likewise, 60.38% of users gave Galecto an outperform vote while only 0.00% of users gave Aspire Biopharma an outperform vote. CompanyUnderperformOutperformAspire BiopharmaOutperform VotesNo VotesUnderperform Votes1100.00% GalectoOutperform Votes3260.38% Underperform Votes2139.62% Is ASBP or GLTO more profitable? Aspire Biopharma's return on equity of 0.00% beat Galecto's return on equity.Company Net Margins Return on Equity Return on Assets Aspire BiopharmaN/A N/A -508.70% Galecto N/A -98.27%-84.29% Do institutionals & insiders believe in ASBP or GLTO? 19.2% of Aspire Biopharma shares are held by institutional investors. Comparatively, 14.2% of Galecto shares are held by institutional investors. 48.0% of Aspire Biopharma shares are held by company insiders. Comparatively, 10.8% of Galecto shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has stronger valuation & earnings, ASBP or GLTO? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAspire BiopharmaN/AN/A-$12.54MN/AN/AGalectoN/AN/A-$21.44M-$15.53-0.22 Which has more risk and volatility, ASBP or GLTO? Aspire Biopharma has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500. Comparatively, Galecto has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500. Do analysts prefer ASBP or GLTO? Galecto has a consensus target price of $10.00, suggesting a potential upside of 198.51%. Given Galecto's stronger consensus rating and higher possible upside, analysts clearly believe Galecto is more favorable than Aspire Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aspire Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Galecto 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer ASBP or GLTO? In the previous week, Aspire Biopharma had 1 more articles in the media than Galecto. MarketBeat recorded 2 mentions for Aspire Biopharma and 1 mentions for Galecto. Aspire Biopharma's average media sentiment score of 0.00 beat Galecto's score of -1.00 indicating that Aspire Biopharma is being referred to more favorably in the media. Company Overall Sentiment Aspire Biopharma Neutral Galecto Negative SummaryGalecto beats Aspire Biopharma on 7 of the 13 factors compared between the two stocks. Get Galecto News Delivered to You Automatically Sign up to receive the latest news and ratings for GLTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GLTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLTO vs. The Competition Export to ExcelMetricGalectoMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.43M$2.79B$5.16B$8.58BDividend YieldN/A2.69%5.38%4.24%P/E Ratio-0.2221.0325.6919.24Price / SalesN/A293.16401.57156.75Price / CashN/A40.9225.4426.73Price / Book0.307.327.865.62Net Income-$21.44M-$55.10M$3.15B$248.36M7 Day Performance0.90%-3.33%-1.54%-0.39%1 Month Performance10.96%5.04%3.38%3.51%1 Year Performance-73.07%-2.47%40.74%15.15% Galecto Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLTOGalecto1.9399 of 5 stars$3.35-0.6%$10.00+198.5%-73.3%$4.43MN/A-0.2240Negative NewsGap DownASBPAspire BiopharmaN/A$0.35-3.4%N/AN/A$17.48MN/A0.00N/AMTEXMannatech1.3961 of 5 stars$9.13-2.9%N/A+43.7%$17.35M$115.04M-11.27250Positive NewsHOTHHoth Therapeutics2.6617 of 5 stars$1.31+0.8%$4.00+205.3%+31.0%$17.30MN/A-0.994News CoverageAnalyst DowngradeGap DownMRKRMarker Therapeutics4.0544 of 5 stars$1.52-5.0%$13.17+766.2%-66.4%$17.20M$6.59M-1.1460High Trading VolumePMNProMIS Neurosciences1.7703 of 5 stars$0.51-2.0%$4.50+784.1%-67.3%$16.64MN/A-5.095Positive NewsBFRGBullfrog AI0.7186 of 5 stars$1.74+3.0%N/A-9.1%$16.38M$60K-2.054LPCNLipocine1.6381 of 5 stars$3.06-1.9%$9.00+194.1%-63.3%$16.37M$3.67M-4.0310News CoverageCASICASI Pharmaceuticals3.6186 of 5 stars$1.33-27.7%$4.00+200.8%-63.8%$16.36M$31.37M-0.60180Positive NewsGap UpHigh Trading VolumeLPTXLeap Therapeutics1.9616 of 5 stars$0.39-4.3%$4.92+1,153.3%-80.2%$16.26MN/A-0.2040News CoverageGap UpFLGCFlora Growth2.2835 of 5 stars$0.70-5.3%$4.00+469.0%-32.5%$15.87M$53.26M-0.72280 Related Companies and Tools Related Companies Aspire Biopharma Competitors Mannatech Competitors Hoth Therapeutics Competitors Marker Therapeutics Competitors ProMIS Neurosciences Competitors Bullfrog AI Competitors Lipocine Competitors CASI Pharmaceuticals Competitors Leap Therapeutics Competitors Flora Growth Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GLTO) was last updated on 6/23/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredThe IRS Loophole That Lets You Own Gold Tax-FreeWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...Advantage Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galecto, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galecto With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GLTO Stock Free GLTO Stock Alerts